GSK Extends $2.6B Offer For Human Genome
Shareholders will now have until June 30 to accept GSK's $13 per-share offer, which the company's reluctant management again blasted as too low.
The tender offer is GSK's backup plan after Maryland-based Human Genome spurned its friendly advances in April. The British drugmaker's most recent per-share overture lured 474,029 shares out...
Already a subscriber? Click here to login